富含血小板血浆治疗乳腺癌幸存者绝经泌尿生殖综合征
这项前瞻性单臂先导研究纳入20例有阴道干涩伴或不伴性交痛的乳腺癌幸存者(0-III期),一次性将7 mL自体富含血小板血浆注射至阴道及后连合35个位点,评估安全性和可行性及6个月疗效。所有参与者完成方案,无严重不良事件,6个月时VAS/VuAS、FSFI、UDI-6、DIVA、VHI及总分较基线显著改善,VMI变化不显著,90.0%患者阴道口径增加,95.0%症状改善。
要点
- 一次性注射7 mL自体PRP至阴道及后连合35个位点安全可行,无严重不良事件。
- 6个月时VAS/VuAS、FSFI、UDI-6、DIVA、VHI及总分较基线显著改善,VMI变化不显著。
- 6个月时90.0%患者阴道口径增加,95.0%患者PGI-I症状改善。
核心结论
- 一次性将自体PRP广泛注射至阴道及后连合安全可行;在这项非对照先导试验中,6个月时治疗显著改善了乳腺癌幸存者(包括正在使用芳香化酶抑制剂者)的GSM症状、性功能、泌尿症状和生活质量。
研究设计与样本
- 前瞻性单臂先导研究,纳入20例有阴道干涩伴或不伴性交痛的乳腺癌幸存者(0-III期),一次性将7 mL自体PRP注射至阴道及后连合35个位点。
主要发现
- 20例参与者平均±标准差年龄53.6±7.5岁,BMI 27.2±4.6;85.0%为激素受体阳性乳腺癌,其中65.0%正在使用芳香化酶抑制剂。
- 所有参与者完成计划方案;不良事件包括阴道点滴出血、刺激、分泌物、烧灼感、痉挛和轻度疼痛,均在24小时内缓解;无严重不良事件。
- VAS/VuAS、FSFI、UDI-6、DIVA、VHI及总分从基线至6个月显著改善;VMI变化不显著。
- 6个月时90.0%患者硅胶扩张器尺寸变化提示阴道口径增加,95.0%患者PGI-I提示症状改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety and feasibility of injection of autologous platelet-rich plasma (PRP) into the vagina and posterior fourchette and to evaluate 6-month efficacy for treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors. METHODS: We conducted a prospective, single-arm pilot study of breast cancer survivors (stage 0-III) who reported vaginal dryness with or without dyspareunia. Participants underwent a one-time treatment with 7 mL autologous PRP injected throughout the vaginal canal and posterior fourchette into 35 sites. The primary outcome was to assess safety and feasibility. Secondary outcomes included VMI (Vaginal Maturation Index), VHI (Vaginal Health Index), VAS/VuAS (Vaginal and Vulvar Assessment Scales), DIVA (Day-to-Day Impact of Vaginal Aging questionnaire), FSFI (Female Sexual Function Index), and UDI-6 (Urogenital Distress Inventory-Short Form) scores. Vaginal caliber was measured with silicone dilators. Patient Global Impression of Improvement (PGI-I) was assessed with a 7-point Likert scale. RESULTS: Twenty participants were treated; mean±SD age and body mass index (BMI) were 53.6±7.5 years and 27.2±4.6, respectively. Most had hormone receptor-positive breast cancer (85.0%), and of those, 65.0% were taking an aromatase inhibitor. All participants completed the planned protocol. Treatment adverse events included vaginal spotting, irritation, discharge, burning, cramping, and mild pain, all resolving within 24 hours. No serious adverse events occurred. VAS/VuAS, FSFI, UDI-6, DIVA, VHI, and total scores showed significant improvement from baseline to 6 months; the VMI change was nonsignificant. At 6 months, 90.0% of patients had an increase in vaginal caliber as measured by change in dilator size, and 95.0% noted improvement of symptoms on PGI-I. CONCLUSION: A single treatment of autologous PRP injected diffusely through the vaginal canal and posterior fourchette is safe and feasible. In this uncontrolled pilot trial, at 6 months, treatment significantly improved GSM symptoms, sexual function, urinary symptoms, and quality of life in breast cancer survivors, including those on aromatase inhibitors. CLINICAL TRIAL REGISTRATION: ClnicalTrials.gov , NCT04535323; Cancer.gov , NCT04535323.
引用
- Chen AH, Trabuco EC, Chumsri S, et al. Platelet-Rich Plasma for Genitourinary Syndrome of Menopause in Breast Cancer Survivors. Obstet Gynecol. 2025. PMID: 40966714. doi:10.1097/AOG.0000000000006081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。